Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-2-3
|
| pubmed:abstractText |
Interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) each has produced a 15%-20% response in metastatic renal cell cancer. Combining IFN-alpha with either IL-2 or 5-fluorouracil (5-FU) enhanced IFN-alpha activity. We have therefore conducted a Phase I Study combining IL-2, IFN-alpha, and 5-FU. The patients were continuously infused with IL-2 (1-3 x 10(6) u/m2) and 5-FU (600-750 mg/m2) for a 5-day period every 28 days, and IFN-alpha (4-5 x 10(6) u/m2) was injected subcutaneously daily. Lymphokine-activated killer (LAK) and natural killer (NK) cell activity was measured on days 0 and 8. Twenty-one patients received 76 courses. All primary tumors were controlled by surgery (81%) or angioinfarction. Hematologic toxicity was mild; median nadir of platelets was 117 K/microL and of granulocytes was 1.2 K/microL. Dose-limiting toxicity included mucositis, liver damage, and hypotension. No treatment-related death occurred, and only one patient required intensive-care-unit support. Two patients had an objective response, one of which was a complete response. Increased LAK cell and NK cell activity occurred at all IL-2 dose levels. Simultaneous delivery of IL-2, IFN-alpha, and 5-FU is safe and shows antitumor and biologic activity. 5-FU did not appear to suppress IL-2-induced LAK and NK cell activation. Maximum tolerated dose of the three-drug combination is IL-2, 2 x 10(6) u/m2, 5-FU 600 mg/m2, and IFN-alpha, 4 x 10(6) u/m2.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1062-8401
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
103-11
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7812360-Adult,
pubmed-meshheading:7812360-Aged,
pubmed-meshheading:7812360-Blood Cell Count,
pubmed-meshheading:7812360-Carcinoma, Renal Cell,
pubmed-meshheading:7812360-Drug Therapy, Combination,
pubmed-meshheading:7812360-Female,
pubmed-meshheading:7812360-Fluorouracil,
pubmed-meshheading:7812360-Humans,
pubmed-meshheading:7812360-Immunologic Factors,
pubmed-meshheading:7812360-Interferon-alpha,
pubmed-meshheading:7812360-Interleukin-2,
pubmed-meshheading:7812360-Kidney Neoplasms,
pubmed-meshheading:7812360-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:7812360-Killer Cells, Natural,
pubmed-meshheading:7812360-Male,
pubmed-meshheading:7812360-Middle Aged,
pubmed-meshheading:7812360-Neoplasm Metastasis,
pubmed-meshheading:7812360-Remission Induction,
pubmed-meshheading:7812360-Severity of Illness Index,
pubmed-meshheading:7812360-Survival Analysis
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
|
| pubmed:affiliation |
Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|